BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30397684)

  • 1. Mathematically universal and biologically consistent astrocytoma genotype encodes for transformation and predicts survival phenotype.
    Aiello KA; Ponnapalli SP; Alter O
    APL Bioeng; 2018 Sep; 2(3):. PubMed ID: 30397684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platform-Independent Genome-Wide Pattern of DNA Copy-Number Alterations Predicting Astrocytoma Survival and Response to Treatment Revealed by the GSVD Formulated as a Comparative Spectral Decomposition.
    Aiello KA; Alter O
    PLoS One; 2016; 11(10):e0164546. PubMed ID: 27798635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSVD- and tensor GSVD-uncovered patterns of DNA copy-number alterations predict adenocarcinomas survival in general and in response to platinum.
    Bradley MW; Aiello KA; Ponnapalli SP; Hanson HA; Alter O
    APL Bioeng; 2019 Sep; 3(3):036104. PubMed ID: 31463421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tensor GSVD of patient- and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survival.
    Sankaranarayanan P; Schomay TE; Aiello KA; Alter O
    PLoS One; 2015; 10(4):e0121396. PubMed ID: 25875127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GSVD comparison of patient-matched normal and tumor aCGH profiles reveals global copy-number alterations predicting glioblastoma multiforme survival.
    Lee CH; Alpert BO; Sankaranarayanan P; Alter O
    PLoS One; 2012; 7(1):e30098. PubMed ID: 22291905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
    van den Bent MJ; Gravendeel LA; Gorlia T; Kros JM; Lapre L; Wesseling P; Teepen JL; Idbaih A; Sanson M; Smitt PA; French PJ
    Clin Cancer Res; 2011 Nov; 17(22):7148-55. PubMed ID: 21914791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective clinical trial experimentally validates glioblastoma genome-wide pattern of DNA copy-number alterations predictor of survival.
    Ponnapalli SP; Bradley MW; Devine K; Bowen J; Coppens SE; Leraas KM; Milash BA; Li F; Luo H; Qiu S; Wu K; Yang H; Wittwer CT; Palmer CA; Jensen RL; Gastier-Foster JM; Hanson HA; Barnholtz-Sloan JS; Alter O
    APL Bioeng; 2020 Jun; 4(2):026106. PubMed ID: 32478280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.
    Korshunov A; Ryzhova M; Hovestadt V; Bender S; Sturm D; Capper D; Meyer J; Schrimpf D; Kool M; Northcott PA; Zheludkova O; Milde T; Witt O; Kulozik AE; Reifenberger G; Jabado N; Perry A; Lichter P; von Deimling A; Pfister SM; Jones DT
    Acta Neuropathol; 2015 May; 129(5):669-78. PubMed ID: 25752754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.
    Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From cytogenetics to cytogenomics: whole-genome sequencing as a first-line test comprehensively captures the diverse spectrum of disease-causing genetic variation underlying intellectual disability.
    Lindstrand A; Eisfeldt J; Pettersson M; Carvalho CMB; Kvarnung M; Grigelioniene G; Anderlid BM; Bjerin O; Gustavsson P; Hammarsjö A; Georgii-Hemming P; Iwarsson E; Johansson-Soller M; Lagerstedt-Robinson K; Lieden A; Magnusson M; Martin M; Malmgren H; Nordenskjöld M; Norling A; Sahlin E; Stranneheim H; Tham E; Wincent J; Ygberg S; Wedell A; Wirta V; Nordgren A; Lundin J; Nilsson D
    Genome Med; 2019 Nov; 11(1):68. PubMed ID: 31694722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
    Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
    Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WHO grade-specific comparative genomic hybridization pattern of astrocytoma - a meta-analysis.
    Holland H; Koschny T; Ahnert P; Meixensberger J; Koschny R
    Pathol Res Pract; 2010 Oct; 206(10):663-8. PubMed ID: 20570053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IDH1 mutation and MGMT expression in astrocytoma and the relationship with prognosis after radiotherapy].
    Jiang M; Dong X; Li J; Li J; Qi J
    Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):668-72. PubMed ID: 25567592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma.
    Schulze Heuling E; Knab F; Radke J; Eskilsson E; Martinez-Ledesma E; Koch A; Czabanka M; Dieterich C; Verhaak RG; Harms C; Euskirchen P
    Mol Cancer Res; 2017 May; 15(5):532-540. PubMed ID: 28148826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
    Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
    Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.
    Yong WH; Shabihkhani M; Telesca D; Yang S; Tso JL; Menjivar JC; Wei B; Lucey GM; Mareninov S; Chen Z; Liau LM; Lai A; Nelson SF; Cloughesy TF; Tso CL
    PLoS One; 2015; 10(10):e0141334. PubMed ID: 26506620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
    Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
    Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.
    Xiu J; Piccioni D; Juarez T; Pingle SC; Hu J; Rudnick J; Fink K; Spetzler DB; Maney T; Ghazalpour A; Bender R; Gatalica Z; Reddy S; Sanai N; Idbaih A; Glantz M; Kesari S
    Oncotarget; 2016 Apr; 7(16):21556-69. PubMed ID: 26933808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.